Abstract
MRD detection using ctDNA analysis after curative treatment may help identify patients at higher risk of relapse and improve treatment outcomes by enabling personalized treatment. We have analyzed the clinical performance of a recently developed tissue-informed, hybrid-capture NGS-based ctDNA MRD assay in CRC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
